Tumor uptake of intravenously administered radiolabeled antibodies in ovarian carcinoma patients in relation to antigen expression and other tumor characteristics
- 21 April 1995
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 64 (2) , 92-98
- https://doi.org/10.1002/ijc.2910640204
Abstract
To study factors that possibly influence the heterogeneous tumor uptake of radiolabeled antibodies, tissues from 34 ovarian‐carcinoma patients were obtained 2 to 8 days after i.v. injection with radiolabeled murine OV‐TL 3 or chimeric MOv 18 (cMOv18). The tumor uptake and the ratio of tumor to normal tissue (T/NT) were studied in relation to the histopathological classification, prior treatment, site of tumor, time interval, antigen expression, volume percentage of (malignant) epithelium in the tumor tissue, and the size of the tumor. The results of immuno‐scintigraphy were also included. In addition, autoradiography using storage phosphor technology was performed on tissue sections from patients injected with iodine‐labeled cMOv18.Tumor uptake varied largely, not only between patients, but also between tumor deposits within the same patient. Uptake of OV‐TL 3 F(ab')2 was higher than of cMOv18 F(ab')2, but the T/NT ratios were similar. The antibody uptake was positively correlated with the pattern of antigen expression and inversely correlated with the time interval between injection and surgery. No correlation was observed with any of the other factors studied. The visibility with immunoscintigraphy was related to the size of the detected lesion, but not to the other factors studied. Autoradiography showed that antibodies preferentially localized in areas with cancer cells, which were immunohisto‐chemically positive for MOv18. In areas with weak antigen expression, autoradiography revealed less activity. The antigen expression by the tumor is an important factor for estimation of the tumor uptake of radiolabeled antibodies.Keywords
This publication has 17 references indexed in Scilit:
- Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19European Journal Of Cancer, 1994
- Biodistribution and Intraoperative Evaluation of Radiolabeled Monoclonal Antibody MX 35 in Patients with Epithelial Ovarian CancerGynecologic Oncology, 1993
- Intra‐patient variation between breast cancer axillary lymph node metastases using quantifiable featuresHistopathology, 1992
- Radioimmunotargeting in ovarian carcinoma patients with indium-111 labeled monoclonal antibody OV-TL 3 F(ab′)2: pharmacokinetics, tissue distribution, and tumor imagingInternational Journal of Gynecologic Cancer, 1992
- Haemodynamic and Transport Barriers to the Treatment of Solid TumoursInternational Journal of Radiation Biology, 1991
- CA 125 and OA 3 as target antigens for immunodiagnosis and immunotherapy in ovarian cancerEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1990
- Autoradiography using storage phosphor technologyElectrophoresis, 1990
- Effect of polarity and differentiation on antibody localization in multicellular tumour spheroid and xenograft models and its potential importance forin vivo IMMUNOTARGETINGInternational Journal of Cancer, 1989
- Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificityInternational Journal of Cancer, 1987
- Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours.Journal of Clinical Pathology, 1986